The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) by investigator assessment compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
radiological progression-free survival
Timeframe: 46 months after first patient entry
progression-free survival per Blinded Independent Central Review (PFS1B)
Timeframe: 96 months after first patient entry